DK0809635T3 - Alfa-Substituerede hydrazider med calpain-hæmmende virkning - Google Patents
Alfa-Substituerede hydrazider med calpain-hæmmende virkningInfo
- Publication number
- DK0809635T3 DK0809635T3 DK96903726T DK96903726T DK0809635T3 DK 0809635 T3 DK0809635 T3 DK 0809635T3 DK 96903726 T DK96903726 T DK 96903726T DK 96903726 T DK96903726 T DK 96903726T DK 0809635 T3 DK0809635 T3 DK 0809635T3
- Authority
- DK
- Denmark
- Prior art keywords
- calpain
- alpha
- inhibitory effect
- processes
- substituted hydrazides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/389,525 US5679680A (en) | 1995-02-16 | 1995-02-16 | α-substituted hydrazides having calpain inhibitory activity |
PCT/US1996/001140 WO1996025403A1 (en) | 1995-02-16 | 1996-01-24 | α-SUBSTITUTED HYDRAZIDES HAVING CALPAIN INHIBITORY ACTIVITY |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0809635T3 true DK0809635T3 (da) | 2002-01-07 |
Family
ID=23538626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96903726T DK0809635T3 (da) | 1995-02-16 | 1996-01-24 | Alfa-Substituerede hydrazider med calpain-hæmmende virkning |
Country Status (11)
Country | Link |
---|---|
US (1) | US5679680A (da) |
EP (1) | EP0809635B1 (da) |
JP (1) | JPH11500124A (da) |
AT (1) | ATE206408T1 (da) |
AU (1) | AU4771396A (da) |
CA (1) | CA2208073A1 (da) |
DE (1) | DE69615664T2 (da) |
DK (1) | DK0809635T3 (da) |
ES (1) | ES2165487T3 (da) |
PT (1) | PT809635E (da) |
WO (1) | WO1996025403A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010768A2 (en) * | 2000-07-31 | 2002-02-07 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
AU2002303218A1 (en) | 2001-04-03 | 2002-11-11 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof |
CA2576258A1 (en) * | 2004-08-09 | 2006-02-16 | Warner-Lambert Company Llc | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
DE102007050673A1 (de) | 2007-10-19 | 2009-04-23 | Friedrich-Schiller-Universität Jena | Neue Hexaaza-acene und Verfahren zu ihrer Herstellung |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA735766B (en) * | 1973-08-22 | 1975-04-30 | Merck & Co Inc | Ethylene generation |
US4169149A (en) * | 1977-01-21 | 1979-09-25 | Giroux Eugene L | Use of α-mercapto-β-arylacrylic acid derivatives in heavy metal poisoning |
US4124718A (en) * | 1977-01-21 | 1978-11-07 | Merrell Toraude Et Compagnie | Enhancing zinc serum and tissue levels |
US4347255A (en) * | 1980-04-17 | 1982-08-31 | Richardson-Merrell Inc. | Snake bite therapy |
US4400382A (en) * | 1980-05-09 | 1983-08-23 | Usv Pharmaceutical Corporation | Thiazoloquinoxalin-1,4-diones for treating allergy |
US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
US4439443A (en) * | 1981-08-07 | 1984-03-27 | Richardson-Merrell Inc. | Snake bite therapy |
JPS60166641A (ja) * | 1984-02-10 | 1985-08-29 | Teijin Ltd | α,β−不飽和カルボン酸類 |
US4999436A (en) * | 1987-09-22 | 1991-03-12 | Merck & Co., Inc. | Aryl-substituted thiophene 3-ols, derivatives and analogs useful as lipoxgenase inhibitors |
DD282006A5 (de) * | 1988-09-13 | 1990-08-29 | Akad Wissenschaften Ddr | Herstellungsverfahren fuer 5-nitrofur-2-yl-olefine |
DK162491D0 (da) * | 1991-09-20 | 1991-09-20 | Novo Nordisk As | Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne |
ES2124281T3 (es) * | 1992-12-25 | 1999-02-01 | Mitsubishi Chem Corp | Derivados de alfa-aminocetonas. |
CA2111930A1 (en) * | 1992-12-25 | 1994-06-26 | Ryoichi Ando | Aminoketone derivatives |
DK31093D0 (da) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
JPH07193474A (ja) * | 1993-12-27 | 1995-07-28 | Sharp Corp | 波形成形回路 |
-
1995
- 1995-02-16 US US08/389,525 patent/US5679680A/en not_active Expired - Fee Related
-
1996
- 1996-01-24 ES ES96903726T patent/ES2165487T3/es not_active Expired - Lifetime
- 1996-01-24 PT PT96903726T patent/PT809635E/pt unknown
- 1996-01-24 JP JP8524969A patent/JPH11500124A/ja not_active Abandoned
- 1996-01-24 CA CA002208073A patent/CA2208073A1/en not_active Abandoned
- 1996-01-24 EP EP96903726A patent/EP0809635B1/en not_active Expired - Lifetime
- 1996-01-24 AT AT96903726T patent/ATE206408T1/de not_active IP Right Cessation
- 1996-01-24 WO PCT/US1996/001140 patent/WO1996025403A1/en active IP Right Grant
- 1996-01-24 AU AU47713/96A patent/AU4771396A/en not_active Abandoned
- 1996-01-24 DK DK96903726T patent/DK0809635T3/da active
- 1996-01-24 DE DE69615664T patent/DE69615664T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH11500124A (ja) | 1999-01-06 |
DE69615664T2 (de) | 2002-08-08 |
ATE206408T1 (de) | 2001-10-15 |
CA2208073A1 (en) | 1996-08-22 |
US5679680A (en) | 1997-10-21 |
WO1996025403A1 (en) | 1996-08-22 |
EP0809635A1 (en) | 1997-12-03 |
PT809635E (pt) | 2002-03-28 |
EP0809635B1 (en) | 2001-10-04 |
DE69615664D1 (de) | 2001-11-08 |
ES2165487T3 (es) | 2002-03-16 |
AU4771396A (en) | 1996-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU93058531A (ru) | Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения | |
DE69434431D1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
DE59608740D1 (de) | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren | |
ATE302194T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
ATE323482T1 (de) | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten | |
DE60142236D1 (de) | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung | |
IS4073A (is) | Nýtt fjölvirknislyf gegn aukningu mótstöðu | |
TR200201094T2 (tr) | Farmasötik maddeler olarak bisiklik amino asitler | |
NO890259D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider. | |
DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
DE69838882D1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
ES2164109T3 (es) | Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf. | |
ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
DK0809635T3 (da) | Alfa-Substituerede hydrazider med calpain-hæmmende virkning | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
MY132077A (en) | Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation | |
DE69917074D1 (de) | Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten | |
ATE425967T1 (de) | Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten | |
ATE214605T1 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
HUP9701150A2 (hu) | Azaxantonszármazékok alkalmazása látászavarok megelőzésére és kezelésére szolgáló gyógyszerkészítmények előállítására | |
CA2534303A1 (en) | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | |
DE69626916T2 (de) | Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten |